Cowen downgraded Jounce Therapeutics (NASDAQ: JNCE) from Outperform to Market Perform.Analyst Boris Peaker cites a lack of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE